Start of up-dosing Up to peak GPS After peak GPS Total
  Patients ADR/Total, N (%), E* Injections ADR/Total, N (%) Patients ADR/Total, N (%), E* Injections ADR/Total, N (%) Patients ADR/Total, N (%), E* InjectionsADR/Total, N (%)
Entiretreatment 122/198 (61.6), 897 764/2396 (31.9) 25/52 (48.1), 208 163/526 (31.0) 147/250 (58.8), 1105 927/2922 (31.7)
Up-dosing to 10,000 SQ-U 105/198 (53.0), 439 350/1236 (28.3) 24/52 (46.2), 124   97/324 (29.7) 129/250 (51.6), 563 447/1560 (28.7)
Plateau with 10,000 SQ-U  45/134 (33.6), 123   97/342 (28.4)   4/18 (22.2), 8   8/37 (43.2)   49/152 (32.2), 131 105/379 (27.7)
Up-dosing to 100,000 SQ-U  81/164(49.4), 293 277/723 (38.3) 16/37 (43.2), 65   55/152 (36.2)   97/201 (48.3), 349 332/875 (37.9)
Maintenance with100,000 SQ-U  28/62 (45.2), 42   40/95 (42.1)   2/8 (25.0), 3   3/10 (30.0)   30/70 (42.9), 45   43/105 (40.6)
*E: Number of events
Table 2: Frequency of Adverse Drug Reactions (ADRs) in patients and injections in the different phases of therapyfor patients who started treatment up to the peak of the grass pollen season (‘up to peak GPS’) or after the end of the grass pollen season (‘after peak GPS’) and total patients.
Goto home»